{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:12:22Z","timestamp":1793142742389,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C18027\/A15790"],"award-info":[{"award-number":["C18027\/A15790"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7852\/A25447"],"award-info":[{"award-number":["C7852\/A25447"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Front\u2010Line therapy in CLL: Assessment of Ibrutinib\u2010containing Regimens (FLAIR) demonstrated improved progression\u2010free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL). This report presents the secondary end\u2010point of health\u2010related quality of life (HR\u2010QoL). FLAIR was a phase 3, open\u2010label, randomised trial across 101 hospitals. Eligible patients were aged 18\u201375\u2009years, World Health Organization performance status (PS) \u22642, requiring treatment; those with &gt;20% 17p deletion were excluded. IR was administered for up to 6\u2009years and FCR for six cycles. Participants completed European Organisation for Research and Treatment of Cancer Quality of Life C30 Questionnaire (EORTC\u2010QLQ\u2010C30), QLQ CLL Module (QLQ\u2010CLL16), three\u2010level EQ\u20105D (EQ\u20105D\u20103L) and EQ5D visual analogue (EQ\u2010VAS) at baseline and follow\u2010up. Function and symptom trajectories were analysed using repeated\u2010measures multilevel regression. 84.4% of participants completed baseline questionnaires and subsequent compliance was 67.6%\u201383.5%. Median age was 63\u2009years; most participants were white and male. HR\u2010QoL trajectories were similar. FCR recipients had worse scores at end of treatment but recovered thereafter. By 48\u2009months, more FCR\u2010treated participants showed meaningful improvements in several scales. Statistically significant differences (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05) favoured IR for physical, role and social function; emotional function favoured FCR. Diarrhoea was more common with IR; fatigue and dyspnoea were more common with FCR, though differences did not exceed minimally important thresholds. Overall, scales were comparable between treatment groups, indicating that continuous IR does not compromise HR\u2010QoL.\n                  <\/jats:p>","DOI":"10.1111\/bjh.70416","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:16:16Z","timestamp":1774923376000},"page":"1596-1607","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient\u2010reported health\u2010related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib\u2013rituximab versus fludarabine\u2013cyclophosphamide\u2013rituximab"],"prefix":"10.1111","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6109","authenticated-orcid":false,"given":"David J.","family":"Allsup","sequence":"first","affiliation":[{"name":"Centre for Biomedicine, Hull York Medical School University of Hull  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-0179","authenticated-orcid":false,"given":"David A.","family":"Cairns","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Faye","family":"Samy","sequence":"additional","affiliation":[{"name":"Frontier Science Scotland  Kingussie UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelia","family":"Duley","sequence":"additional","affiliation":[{"name":"CLL Support  Chippenham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[{"name":"The Christie Hospital NHS Foundation Trust  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Varghese","sequence":"additional","affiliation":[{"name":"Leeds Cancer Centre, Leeds Teaching Hospitals Trust  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meads","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, Leeds Institute of Health Sciences University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"Dawkins","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, Leeds Institute of Health Sciences University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Girvan","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena R.","family":"Howard","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Brown","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Jackson","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Greatorex","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Templeton","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tupper","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Phillips","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Yaqub","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Mortimer","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stones","sequence":"additional","affiliation":[{"name":"Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-3034","authenticated-orcid":false,"given":"Piers E. M.","family":"Patten","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centre King's College London  London UK"},{"name":"Department of Haematology King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-9790","authenticated-orcid":false,"given":"Andrew","family":"Rawstron","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service (HMDS), Leeds Cancer Centre Leeds Teaching Hospitals Trust  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"Leeds Cancer Centre, Leeds Teaching Hospitals Trust  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"Leeds Cancer Centre, Leeds Teaching Hospitals Trust  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Haematology Malignancy Research Network.Prevalence CLL (by age)2025Available from:https:\/\/hmrn.org\/statistics\/prevalence"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199175"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00144-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004190"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00150-0"},{"key":"e_1_2_10_13_1","unstructured":"CLL Support.Second National CLL Survey: March \u2013 April 20242024Available from:https:\/\/cll1prod.wpengine.com\/wp\u2010content\/uploads\/2024\/09\/Survey\u2010results\u20102024.pdf."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07407.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020195"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2262378"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113927"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1_3"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150462"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.96"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26483"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26260"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1986217"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1718-y"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18072"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1529"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.155986"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70416","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:10:37Z","timestamp":1780906237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/bjh.70416"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70416","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"2025-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}